Board Change

RNS Number : 1652M

Retroscreen Virology Group PLC

14 July 2014

 



For immediate release 07.00: 14 July 2014

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

BOARD CHANGE

Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human challenge models of disease, is pleased to announce that Dr Alison Fielding has been appointed as a Non-Executive Director of the Company with immediate effect.

Alison is a highly respected, entrepreneurial leader, executive coach and mentor with extensive board experience in both Executive and Non-Executive capacities in public, private and not-for-profit sectors. She has a track record of creating and building high-performing companies based on scientific innovation.

Alison is Director of IP Impact at IP Group plc, a leading UK intellectual property commercialisation company. She co-founded Techtran Group Limited and was the Chief Operating Officer of Techtran when it was acquired by IP Group in January 2005. She was a Director of IP Group from January 2005 to June 2013, promoted to Chief Technology officer in March 2007 and then Chief Operating Officer in May 2011. She spent six years at McKinsey & Co from 1994 to 2000, where she consulted primarily to the pharmaceutical and health care sectors. Prior to McKinsey, she spent four years as a development chemist for Zeneca, performing technical roles in the speciality chemicals and agrochemicals divisions. Alison holds an MBA from Manchester Business School, a Ph.D. in Organic Chemistry and a first class degree in Chemistry from the University of Glasgow.

Kym Denny, Chief Executive Officer, commented, "I am delighted to welcome Alison to Retroscreen's newly shaped Board, at this exciting juncture in the Company's development. Alison has a tremendous track record of working with growth companies in the life science sector to achieve their potential. We look forward to benefitting from her expertise, as we actively broaden Retroscreen's capabilities in our quest to leverage fully our unique hVIVO technology platform."

Dr Alison Margaret Fielding (49) is a director/ partner or has been a director/ partner of the following companies/ partnerships during the previous five years:

Current 

Getech Group plc

Green Chemicals plc

Perachem Limited

Tissue Regenix Group plc

Previous

Amaethon Limited

Amaethon Trustees Limited

Care International UK

COE Group plc

Crysalin Limited

Fusion IP plc

IP Group Plc

IP2IPO Limited

IP2IPO Services Limited

IP Industry Partners Limited

Techtran Group Limited

Techtran Limited

Techtran Corporate Finance Limited

Techtran Investments Limited

Techtran Services Limited

Pure Polymers Limited

Top Technology Ventures Limited

The Foundation for Social Entrepreneurs

Dr Fielding holds 24,320 ordinary shares in the Company, which were acquired prior to the Company's IPO in May 2012.

Save for the information disclosed above there is no other information to be disclosed on Dr Fielding under Schedule 2(g) of the AIM Rules.

For further information please contact:

Retroscreen Virology Group plc                                                         [phone]

Kym Denny (CEO)

Graham Yeatman (FD)

Numis Securities Limited                                                                   [phone]

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.

Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors.  To date, the Company has conducted over 35 clinical studies, involving more than 1600 volunteers for a range of leading industry, governmental and academic clients.

However, Retroscreen's hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.

 

END

 

 

BOAQKDDQOBKDPOD